RxDoctor Payments Data

Subooha Zafar, MD

Sleep Medicine · Hamilton, NJNPI 1902858665

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.9% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 33.5% of the total. Reporting peaked in 2023 at $389 and has fallen 66.2% since, to $131 in 2025. That places this record below the midpoint for sleep medicine clinicians in NJ, where the typical reported total is $1,341.

$901in general payments, 2019–2025

Across 45 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$302
  • Jazz Pharmaceuticals Inc.$208
  • Harmony Biosciences LLC$157
  • Idorsia Pharmaceuticals US Inc$96
  • Axsome Therapeutics, Inc.$53
  • Merck$30
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$84694%
  • Education$556%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$901 in reported general payments places this provider in the 35th percentile of 40 sleep medicine providers in New Jersey.

See all sleep medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$45,630
Medicare patients
223
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant23$13,834
QuviviqDaridorexant Hcl21$10,706
Doxepin Hcl54$8,382
Gabapentin114$1,220
Zolpidem Tartrate40$404
Trazodone Hcl72$384
Montelukast Sodium28$372
Modafinil23$315
Ropinirole Hcl14$269
Clonazepam28$149
Fluoxetine Hcl13$20

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckBelsomra$30$13,83423 claims
Idorsia Pharmaceuticals US IncQuviviq$96$10,70621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 40 sleep medicine providers in New Jersey.

Other sleep medicine in Hamilton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →